← Back to patent-cliff list
利格列汀/恩格列净
Tier C — Watch / tradeLinagliptin/Empagliflozin
勃林格殷格翰
Originator
2015
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：DPP4、SGLT2
Brand：Glyxambi、Tradiance、Esgliteo
Indications (approved)：心脏和血管疾病、二型糖尿病
Regional status
US
批准上市
2015-01-30
EU
批准上市
2016-11-11
China
-
Japan
批准上市
2018-09-21
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Linagliptin/Empagliflozin?
Approved indications include: 心脏和血管疾病, 二型糖尿病.
When does the Linagliptin/Empagliflozin patent expire?
No public expiry year is available for Linagliptin/Empagliflozin yet; this page updates once verified.
How do I get a quote for Linagliptin/Empagliflozin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24